Field Medical Secures $35 Million to Propel Innovative Cardiac Ablation Technology Forward
Field Medical Secures $35 Million to Propel Innovative Cardiac Ablation Technology Forward
In a significant milestone for cardiac care, Field Medical, Inc. reveals its successful closing of a $35 million Series B financing round. This round was co-led by BioStar Capital and Cue Growth, with support from existing investors. It aims to facilitate the development of the company’s groundbreaking FieldForce™ Pulsed Field Ablation (PFA) technology, setting the stage for more effective treatment of complex cardiac conditions, particularly ventricular tachycardia (VT).
Founded in 2022, Field Medical is a clinical-stage company dedicated to transforming cardiac ablation procedures through its advanced PFA technology. The FieldForce™ Ablation System is designed specifically for transmural lesion creation, a crucial area in VT treatment. The new funding will significantly bolster the company’s ability to initiate its pivotal VERITAS trial, enhancing its research and development capabilities, aiming to redefine the landscape of VT care.
Notably, the financial backing has been spurred by robust pilot data showcased at the 2025 Heart Rhythm Society meeting. To date, the company has successfully raised a total of $75 million, underscoring its position as a leader in the innovation of PFA solutions for complex arrhythmias. Steven Mickelsen, MD, Founder and CEO of Field Medical, expressed optimism regarding their unique approach: "Ventricular tachycardia is among the most underpenetrated segments in electrophysiology; however, physicians require better tools to effectively address this condition. Our therapeutic advancements are aligned to meet this pressing clinical need."
Dr. Mickelsen draws parallels between the current status of VT care and the early days of atrial fibrillation (AF) treatment, where there was strong clinical demand, but existing technologies fell short. He further added that the company is in a favorable position to capitalize on this growing need, with a system aimed at speed, precision, and real clinical outcomes.
Enhanced Board Leadership
As Field Medical embarks on its next phase of growth, the company announced updates to its Board of Directors to strengthen its governance. The new members comprise industry veterans:
- - Mark Wisniewski, CFO of Enterra Medical, will lead as chairperson, bringing strategic financial insights.
- - Marlou Janssen, an experienced board member in medtech, adds valuable commercial and clinical strategy leadership gained through her work in notable companies within the industry.
- - Alexei Mlodinow, a surgeon by training, enriches the team with a successful entrepreneurial background in medtech innovation.
- - Ben Cannon, a founding partner at Cue Growth, contributes his venture capital expertise to support Field Medical’s scaling efforts.
The new composition is poised to guide Field Medical through its ambitious plans while ensuring that innovation remains at the forefront of their agenda.
Innovative Future Ahead
Field Medical’s commitment to excellence is evident in its distinctive approach to PFA technology, which combines advanced catheter design with proprietary FieldBending™ energy, facilitating rapid and targeted ablation processes. The company received the Breakthrough Device Designation in 2024 and was selected for the FDA TAP Pilot Program concerning its VT indications, marking significant achievements in its journey so far.
To educate interested parties, the company emphasizes its findings through various channels. Those eager to learn more can view the Heart Rhythm 2025 Satellite Symposium replay, aptly titled PFA in the Ventricle: The Future of Ablation.
As they continue to make significant strides towards reshaping VT treatment, Field Medical is poised to expand its role within the electrophysiology field, leading with innovation and a dedication to patient care. To stay updated, you can visit their official website, Field Medical Inc., and follow their advances on social media platforms.
Please note the FieldForce™ Ablation System is an investigational device, limited by federal law to investigational use only.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.